Skip to main content
Livermore
Livermore
ZHEN

Redmile Group, LLC

SEC CIK
0001425738
Latest filing
Aug 14, 2026

CLDX holding history

Celldex Therapeutics, Inc. in every 13F filed by Redmile Group, LLC, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

CLDX overviewAll 13F holders of CLDXFull Q2 2026 holdings

Shares (Q2 2026)
433,921
Value
$16.1M
% of portfolio
1.1%
Quarters held
22
Since Q1 2021
Holdings of CLDX by Redmile Group, LLC, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 2026433,921$16.1M1.1%+172,413+65.9%AddedHolders
Q1 2026261,508$8.30M0.5%−21,800−7.7%ReducedHolders
Q4 2025283,308$7.69M0.6%−43,700−13.4%ReducedHolders
Q3 2025327,008$8.46M0.8%−16,018−4.7%ReducedHolders
Q2 2025343,026$6.98M0.7%−247,149−41.9%ReducedHolders
Q1 2025590,175$10.7M1.0%−25,600−4.2%ReducedHolders
Q4 2024615,775$15.6M1.1%−41,400−6.3%ReducedHolders
Q3 2024657,175$22.3M1.3%−61,548−8.6%ReducedHolders
Q2 2024718,723$26.6M1.6%−177,731−19.8%ReducedHolders
Q1 2024896,454$37.6M1.4%−97,349−9.8%ReducedHolders
Q4 2023993,803$39.4M1.4%−642,135−39.3%ReducedHolders
Q3 20231,635,938$45.0M2.1%−60,066−3.5%ReducedHolders
Q2 20231,696,004$57.5M2.2%−183,735−9.8%ReducedHolders
Q1 20231,879,739$67.6M2.9%−97,712−4.9%ReducedHolders
Q4 20221,977,451$88.1M3.6%−7,700−0.4%ReducedHolders
Q3 20221,985,151$55.8M2.2%−85,137−4.1%ReducedHolders
Q2 20222,070,288$55.8M2.1%+24,019+1.2%AddedHolders
Q1 20222,046,269$69.7M2.2%−119,317−5.5%ReducedHolders
Q4 20212,165,586$83.7M1.9%−877,712−28.8%ReducedHolders
Q3 20213,043,298$164.3M2.9%+31,217+1.0%AddedHolders
Q2 20213,012,081$100.7M1.5%−375,707−11.1%ReducedHolders
Q1 20213,387,788$69.8M1.0%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.